Polypharmacy and Multimorbidity Among Medicaid Enrollees: A Multistate Analysis
Polypharmacy and Multimorbidity Among Medicaid Enrollees: A Multistate Analysis
复制标题
DOI：
10.1089/pop.2017.0065
复制
发表时间：
2018-04-01
影响因子：
2.5
通讯作者：
Sambamoorthi, Usha
中科院分区：
文献类型：
--
作者：
Feng, Xue;Tan, Xi;Sambamoorthi, Usha
本研究的目的是探讨多药治疗和多药使用传统和新的措施之间的关联。在这项横断面研究中，年龄在18-64岁且至少患有1种慢性疾病的按服务付费（FFS）医疗补助计划参与者（N= 38，329）的数据来自马里兰州和西弗吉尼亚州的2010年医疗补助分析扩展（MAX）文件。根据作者的新定义，多重用药被确定为连续60天同时使用5种药物。根据美国卫生和人类服务部框架，多发病定义为患有2种慢性疾病。采用卡方检验和logistic回归分析多药治疗与多药治疗之间的相关性。使用新定义估计的多药患病率为50.9%，而使用2种常用的传统测量方法分别为16.7%和64.9%。对于所有3种定义，患有多药症的个体比没有多药症的个体更可能患有多药症（P
The purpose of this study is to explore the associations between polypharmacy and multimorbidity using conventional and novel measures of polypharmacy. In this cross-sectional study, data on fee-for-service (FFS) Medicaid enrollees with at least 1 chronic condition and aged 18-64 years (N=38,329) were derived from the 2010 Medicaid Analytic eXtract (MAX) files of Maryland and West Virginia. Polypharmacy, by the authors' novel definition, was determined as simultaneous use of 5 drugs for a consecutive period of 60 days. Multimorbidity was defined as having 2 chronic conditions based on the US Department of Health and Human Services framework. The association between multimorbidity and polypharmacy was examined with chi-square tests and logistic regression. Polypharmacy prevalence was estimated at 50.9% using the novel definition, as compared to 16.7% and 64.9% for the 2 commonly used conventional measures, respectively. For all 3 definitions, individuals with multimorbidity were more likely to have polypharmacy than those without multimorbidity (P